Skip to main content
Top
Published in: Journal of Prevention 4/2008

01-07-2008 | Original Paper

Predicting the Effectiveness of Prevention: A Role for Epidemiological Modeling

Authors: Helen L. Walls, Anna Peeters, Christopher M. Reid, Danny Liew, John J. McNeil

Published in: Journal of Prevention | Issue 4/2008

Login to get access

Abstract

It is well known that the current combination of aging populations and advances in health technology is resulting in burgeoning health costs in developed countries. Prevention is a potentially important way of containing health costs. In an environment of intense cost pressures, coupled with developments in disease prevention and health promotion, it is increasingly important for decision-makers to have a systematic, coordinated approach to the targeting and prioritization of preventive strategies. However, such a systematic approach is made difficult by the fact that preventive strategies need to be compared over the long term, in a variety of populations, and in real life settings not found in most trials. Information from epidemiological models can provide the required evidence base. In this review, we outline the role of epidemiological modeling in this context and detail its application using examples. Editors’ Strategic Implications: Policymakers and researchers will benefit from this description of the utility of epidemiological modeling as a means of generating translational evidence that helps to prioritize data-based prevention approaches and bridge the gap between clinical research and public health practice.
Literature
go back to reference Barendregt, J. J., Bonneux, L., & Van Der Maas, P. J. (1997). The health care costs of smoking. New England Journal of Medicine, 337, 1052–1057.PubMedCrossRef Barendregt, J. J., Bonneux, L., & Van Der Maas, P. J. (1997). The health care costs of smoking. New England Journal of Medicine, 337, 1052–1057.PubMedCrossRef
go back to reference Beir, V. M. (2001). On the state of the art: Risk communication to the public. Reliability Engineering and System Safety, 71, 139–150.CrossRef Beir, V. M. (2001). On the state of the art: Risk communication to the public. Reliability Engineering and System Safety, 71, 139–150.CrossRef
go back to reference Brandeau, M., Zaric, G., & De Angelis, V. (2005). Improved allocation of HIV prevention resources: Using information about prevention program production functions. Health Care Management Science, 8, 19–28.PubMedCrossRef Brandeau, M., Zaric, G., & De Angelis, V. (2005). Improved allocation of HIV prevention resources: Using information about prevention program production functions. Health Care Management Science, 8, 19–28.PubMedCrossRef
go back to reference Doran, E., & Henry, D. (2006). Pharmaceutical benefits scheme policy: Confused and tough on patients. Internal Medicine Journal, 36, 211–213.PubMedCrossRef Doran, E., & Henry, D. (2006). Pharmaceutical benefits scheme policy: Confused and tough on patients. Internal Medicine Journal, 36, 211–213.PubMedCrossRef
go back to reference Edwards, A., Elwyn, G., & Mulley, A. (2002). Explaining risks: Turning numerical data into meaningful pictures. British Medical Journal, 324, 827–830.PubMedCrossRef Edwards, A., Elwyn, G., & Mulley, A. (2002). Explaining risks: Turning numerical data into meaningful pictures. British Medical Journal, 324, 827–830.PubMedCrossRef
go back to reference Ford, E. S., Ajani, U. A., Croft, J. B., Critchely, J., Labarthe, D. R., Kottke, T. E., et al. (2007). Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. New England Journal of Medicine, 356, 2388.PubMedCrossRef Ford, E. S., Ajani, U. A., Croft, J. B., Critchely, J., Labarthe, D. R., Kottke, T. E., et al. (2007). Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. New England Journal of Medicine, 356, 2388.PubMedCrossRef
go back to reference Franco, O. H., Peeters, A., Looman, C. W., & Bonneux, L. (2005). Cost effectiveness of statins in coronary heart disease. Journal of Epidemiology and Community Health, 59, 927–933.PubMedCrossRef Franco, O. H., Peeters, A., Looman, C. W., & Bonneux, L. (2005). Cost effectiveness of statins in coronary heart disease. Journal of Epidemiology and Community Health, 59, 927–933.PubMedCrossRef
go back to reference Fries, J. F. (1980). Aging, natural death, and the compression of morbidity. New England Journal of Medicine, 303, 130–135.PubMed Fries, J. F. (1980). Aging, natural death, and the compression of morbidity. New England Journal of Medicine, 303, 130–135.PubMed
go back to reference Haddix, A., Teutsch, S. M., & Corso, P. S. (2003). Prevention effectiveness: A guide to decision analysis and economic evaluation, (2nd ed., pp. 264). Oxford: Oxford University Press. ISBN: 0-19-514897-5. Haddix, A., Teutsch, S. M., & Corso, P. S. (2003). Prevention effectiveness: A guide to decision analysis and economic evaluation, (2nd ed., pp. 264). Oxford: Oxford University Press. ISBN: 0-19-514897-5.
go back to reference Jackson, R. (2001). Are the new lipid management guidelines good for Australia’s health? Medical Journal of Australia, 175, 452–453.PubMed Jackson, R. (2001). Are the new lipid management guidelines good for Australia’s health? Medical Journal of Australia, 175, 452–453.PubMed
go back to reference Johnson, K., & Lassere, M. (2003). Letters—Epidemiological modelling (including economic modelling) and its role in preventive drug therapy. Medical Journal of Australia, 178, 188.PubMed Johnson, K., & Lassere, M. (2003). Letters—Epidemiological modelling (including economic modelling) and its role in preventive drug therapy. Medical Journal of Australia, 178, 188.PubMed
go back to reference Liew, D., McNeil, J., Peeters, A., Lim, S., & Vos, T. (2002). Epidemiological modelling (including economic modelling) and its role in preventive drug therapy. Medical Journal of Australia, 177, 364–367.PubMed Liew, D., McNeil, J., Peeters, A., Lim, S., & Vos, T. (2002). Epidemiological modelling (including economic modelling) and its role in preventive drug therapy. Medical Journal of Australia, 177, 364–367.PubMed
go back to reference Lim, S., Vos, T., Peeters, A., Liew, D., & McNeil, J. (2001). Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria. Medical Journal of Australia, 175, 459–464.PubMed Lim, S., Vos, T., Peeters, A., Liew, D., & McNeil, J. (2001). Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria. Medical Journal of Australia, 175, 459–464.PubMed
go back to reference Malenka, D. J., Baron, J. A., Johansen, S., Wahrenberger, J. W., & Ross, J. (1993). The framing effect of relative and absolute risk. Journal of General Internal Medicine, 8, 543–548. Malenka, D. J., Baron, J. A., Johansen, S., Wahrenberger, J. W., & Ross, J. (1993). The framing effect of relative and absolute risk. Journal of General Internal Medicine, 8, 543–548.
go back to reference Mamun, A. A., Peeters, A., Barendregt, J. J., Willekens, F., Nusselder, W. J., & Bonneux, L. (2004). Smoking decreases the duration of life lived with and without cardiovascular disease: A life course analysis of the Framingham heart study. European Heart Journal, 25, 409–415.PubMedCrossRef Mamun, A. A., Peeters, A., Barendregt, J. J., Willekens, F., Nusselder, W. J., & Bonneux, L. (2004). Smoking decreases the duration of life lived with and without cardiovascular disease: A life course analysis of the Framingham heart study. European Heart Journal, 25, 409–415.PubMedCrossRef
go back to reference Marshall, T. (2003). Coronary heart disease prevention: Insights from modelling incremental cost effectiveness. British Medical Journal, 327, 1264–1275.PubMedCrossRef Marshall, T. (2003). Coronary heart disease prevention: Insights from modelling incremental cost effectiveness. British Medical Journal, 327, 1264–1275.PubMedCrossRef
go back to reference Mathers, C. D., & Loncar, D. (2005). Updated projections of global mortality and burden of disease, 2002–2030: Data sources, methods and results. Evidence and information for policy. Geneva: World Health Organization. Mathers, C. D., & Loncar, D. (2005). Updated projections of global mortality and burden of disease, 2002–2030: Data sources, methods and results. Evidence and information for policy. Geneva: World Health Organization.
go back to reference McEwan, P., Peters, J. R., Bergenheim, K., & Currie, C. J. (2006). Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Current Medical Research Opinion, 22, 121–129.CrossRef McEwan, P., Peters, J. R., Bergenheim, K., & Currie, C. J. (2006). Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Current Medical Research Opinion, 22, 121–129.CrossRef
go back to reference McNeil, J., Peeters, A., Liew, D., Lim, S., & Vos, T. (2001). A model for predicting the future incidence of coronary heart disease within percentiles of coronary heart disease risk. Journal of Cardiovascular Risk, 8, 31–37.PubMedCrossRef McNeil, J., Peeters, A., Liew, D., Lim, S., & Vos, T. (2001). A model for predicting the future incidence of coronary heart disease within percentiles of coronary heart disease risk. Journal of Cardiovascular Risk, 8, 31–37.PubMedCrossRef
go back to reference Murray, C. J. L., & Lopez, A. D. (1997). Mortality by cause for eight regions of the world: Global burden of disease study. The Lancet, 349, 1269–1276.CrossRef Murray, C. J. L., & Lopez, A. D. (1997). Mortality by cause for eight regions of the world: Global burden of disease study. The Lancet, 349, 1269–1276.CrossRef
go back to reference Nelson, M., Liew, D., Bertram, M., & Vos, T. (2005). Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥70. British Medical Journal, 327, 1–6. Nelson, M., Liew, D., Bertram, M., & Vos, T. (2005). Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥70. British Medical Journal, 327, 1–6.
go back to reference Peeters, A., Bonneaux, L., Barendregt, J. J., & Mackenbach, J. P. (2003). Improvements in treatment of coronary heart disease and cessation of stroke mortality rate decline. American Stroke Association, 34, 1610–1614. Peeters, A., Bonneaux, L., Barendregt, J. J., & Mackenbach, J. P. (2003). Improvements in treatment of coronary heart disease and cessation of stroke mortality rate decline. American Stroke Association, 34, 1610–1614.
go back to reference Pike, R., Keech, A., & Simes, R. (2003). Clinical trials research in the new millennium: The International Clinical Trials Symposium, Sydney, 21–23 October 2002. Medical Journal of Australia, 178, 316–317.PubMed Pike, R., Keech, A., & Simes, R. (2003). Clinical trials research in the new millennium: The International Clinical Trials Symposium, Sydney, 21–23 October 2002. Medical Journal of Australia, 178, 316–317.PubMed
go back to reference Reid, C., Meehan, A., Owen, A., Wlodarczyk, J., Robb, T., Hardy, M., et al. (2006). The Bosentan patient registry. In Proceedings of the National Medicines Symposium, Canberra, AU. Reid, C., Meehan, A., Owen, A., Wlodarczyk, J., Robb, T., Hardy, M., et al. (2006). The Bosentan patient registry. In Proceedings of the National Medicines Symposium, Canberra, AU.
go back to reference Simes, R. (2002). Clinical trails and “real-world” medicine. Medical Journal of Australia, 177, 410–411.PubMed Simes, R. (2002). Clinical trails and “real-world” medicine. Medical Journal of Australia, 177, 410–411.PubMed
go back to reference Simon, G., Wagner, E., & Vonkorff, M. (1995). Cost-effectiveness comparisons using “real-world” randomized trials: The case of new antidepressant drugs. Journal of Clinical Epidemiology, 48, 363–373.PubMedCrossRef Simon, G., Wagner, E., & Vonkorff, M. (1995). Cost-effectiveness comparisons using “real-world” randomized trials: The case of new antidepressant drugs. Journal of Clinical Epidemiology, 48, 363–373.PubMedCrossRef
go back to reference Stocks, N., Allan, J., & Mansfield, P. R. (2005). Management of hyperlipidaemia. Australian Family Physician, 34, 447–453.PubMed Stocks, N., Allan, J., & Mansfield, P. R. (2005). Management of hyperlipidaemia. Australian Family Physician, 34, 447–453.PubMed
go back to reference Unal, B., Capewell, S., & Critchley, J. A. (2006). Coronary heart disease policy models: A systematic review. BMC Public Health, 6, 213.PubMedCrossRef Unal, B., Capewell, S., & Critchley, J. A. (2006). Coronary heart disease policy models: A systematic review. BMC Public Health, 6, 213.PubMedCrossRef
go back to reference Zhang, P., Engelgau, M. M., Norris, S. L., Gregg, E. W., & Narayan, K. M. V. (2004). Application of economic analysis to diabetes and diabetes care. Annals of Internal Medicine, 140, 972–977.PubMed Zhang, P., Engelgau, M. M., Norris, S. L., Gregg, E. W., & Narayan, K. M. V. (2004). Application of economic analysis to diabetes and diabetes care. Annals of Internal Medicine, 140, 972–977.PubMed
Metadata
Title
Predicting the Effectiveness of Prevention: A Role for Epidemiological Modeling
Authors
Helen L. Walls
Anna Peeters
Christopher M. Reid
Danny Liew
John J. McNeil
Publication date
01-07-2008
Publisher
Springer US
Published in
Journal of Prevention / Issue 4/2008
Print ISSN: 2731-5533
Electronic ISSN: 2731-5541
DOI
https://doi.org/10.1007/s10935-008-0143-y

Other articles of this Issue 4/2008

Journal of Prevention 4/2008 Go to the issue